Skip to content
ApprovedFDA approved

Raloxifene (Evista)

Prescription SERM for bone loss after menopause, also used by men for breast enlargement; its main risk is venous blood clots.

Available at

The links above are labelled third-party affiliate links. MolekulaX does not sell and does not verify product quality.

Raloxifene (Evista) vial

DETAILED OVERVIEW

What is Raloxifene (Evista)?

Raloxifene is a prescription medicine sold as Evista. It is a selective estrogen receptor modulator (SERM): it blocks estrogen in the breast and womb but partly imitates it in bone. In the United States it was approved in 1997 for bone loss after menopause, and later also to prevent breast cancer in high-risk women. Men using anabolic steroids also use it to reverse breast enlargement (gynecomastia); only a few small studies in adolescents exist for this.

Its most serious risk is venous blood clots (deep vein thrombosis, pulmonary embolism). The US prescribing information carries its strongest, boxed warning about this: the risk is about three times higher than with placebo. In people with existing coronary artery disease or high cardiovascular risk, deaths from stroke also increased. Hot flashes are very common. It must not be used in pregnancy, because it can harm the baby. It is on the anti-doping list and banned for male athletes.

Mechanism

Benzothiophene SERM, ER-α antagonist in breast+uterus, agonist in bone

Half-life

~27 h (once-daily dose)

Onset

Gyno-tissue regression 6-12 weeks

Legal status

FDA + EMA Rx (postmenopausal osteo + breast-cancer prevention), WADA S4 (banned)

Data console

Lab data

Androgenic:AnabolicN/A (not an AAS, SERM)
AR bindingER-α competitive affinity high (Ki ~50 nM), ER-β lower.…
Active half-life~27 hours (no active metabolite, parent compound is the main agent)
Detection windowWADA-accredited GC-MS/LC-MS/MS urine detection ~1-2 months (raloxifene-glucuronide metabolite marker).
AromatizationDoes not aromatize – selective ER-α antagonist (breast + uterus), partial agonist in bone. NOT a CYP19 inhibitor. Does not directly affect the aromatase axis.
HepatotoxicityLow – non-steroidal, not 17α-alkylated. FDA Evista label hepatic adverse events <2% incidence. Glucuronidation primary metabolism (NOT CYP-mediated → fewer DDIs).

Safety

Side effects, stop signs, contraindications

Side effects · 6

  • Venous thromboembolism (deep vein thrombosis, pulmonary embolism) – FDA Evista black-box warning, roughly 3-fold increased relative risk vs placebo, highest during the first 4 months.
  • Hot flashes – common (around 25-30%), especially in the first months of treatment, a consequence of the SERM estrogen-antagonist effect.
  • Leg cramps and muscle spasms – well-documented, common adverse effect in the Evista trials.
  • Peripheral edema (fluid retention, leg swelling) – a common complaint.
  • Flu-like syndrome, joint pain (arthralgia) and sweating – among the milder, frequently reported side effects.
  • Increased risk of fatal stroke documented in women with proven coronary heart disease or at high cardiovascular risk (RUTH trial) – overall stroke incidence was not raised, but fatal outcomes were.

Contraindications · 7

  • Active or past venous thromboembolic event (deep vein thrombosis, pulmonary embolism, retinal vein thrombosis) – absolute contraindication per FDA Evista label.
  • Pregnancy and women who may become pregnant, plus breastfeeding – Pregnancy Category X, teratogenic, contraindicated in women of childbearing potential.
  • Prolonged immobilization (post-surgical recovery, long travel, bed rest) – due to VTE risk; should be stopped at least 72 hours before immobilization and not resumed until full mobility returns.
  • Established coronary heart disease, prior stroke or high cardiovascular risk – fatal stroke risk was increased in the RUTH trial.
  • Severe hepatic impairment (liver insufficiency) – insufficient safety data, caution or avoidance advised.
  • Severe renal impairment – limited data, cautious use required.
  • Unexplained uterine bleeding or endometrial abnormality – must be investigated before starting raloxifene.

Related Performance Compounds

Same therapeutic category

Studies

Related research and clinical findings

Telegram

Have a question about Raloxifene (Evista)?

Reach out to an advisor on Telegram. Performance compounds are presented with a harm-reduction approach, based on peer-reviewed evidence.

Personalized consultation

Want a detailed conversation tailored to your data?

Fill out the prep intake form (your goals, training and health data), and the advisor prepares from it to give genuinely personalized guidance.

Fill out the form

~5–7 min · prep questionnaire · confidential · GDPR-compliant

MolekulaX Editorial Team·Source-verified · PubMed · FDA · EMA
Updated: October 14, 2026

The information here is for educational and scientific purposes only. Performance-enhancing compounds (AAS, prohormones, stimulants, doping agents) are illegal without prescription in Hungary and most of the EU, and carry serious health and legal risks. WADA bans them in competitive sport. This is NOT a usage guide, and we do not encourage any illegal use. If you do use them, medical supervision and regular bloodwork are ESSENTIAL. Severe endocrine, cardiovascular, hepatic and psychiatric side effects are possible.